SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Core Insights - Rezolute, Inc. shares experienced a significant decline on December 11, 2025, due to disappointing topline results from its Phase 3 sunRIZE clinical trial for ersodetug, its lead drug candidate for treating congenital hyperinsulinism [1] - The clinical trial did not meet its primary and key secondary endpoints, with the highest dose showing reductions in hypoglycemia events that were not statistically significant compared to placebo [1] Company Performance - The failure of the Phase 3 trial has led to a sharp drop in investor confidence, impacting the stock price of Rezolute, Inc. [1] - The results indicate potential challenges for the company's lead drug candidate, which may affect future development and funding opportunities [1]